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doi:10.1016/j.jtcvs.2006.06.051bjectives: Minimally invasive endoscopic treatment of emphysema could provide
alliation with less risk than lung volume reduction surgery and offer therapy to
atients currently not considered for lung volume reduction surgery. The Intrabron-
hial Valve is used to block bronchial airflow in the most emphysematous areas of
ung.
ethods: Patients with severe chronic obstructive pulmonary disease and hetero-
eneous upper lobe–predominant emphysema were eligible. Patients underwent
exible bronchoscopic placement of valves into segmental or subsegmental airways
n both upper lobes. Outcomes assessed over a minimum of 6 months of follow-up
ncluded the safety, feasibility, tolerance, and success of valve placement; health-
elated quality of life; exercise capacity; pulmonary function; and gas exchange.
esults: Five centers treated 30 patients. Patient follow-up ranged from 1 to 12
onths. A mean of 6.1 valves were placed per patient. Valves were positioned by
eans of flexible bronchoscopy in 99% of desired airways, and the procedure
uration ranged from 15 to 125 minutes (mean, 65 minutes). Hospital discharge
ccurred within 2 days in 27 of 30 patients. There were no deaths or episodes of
alve migration, tissue erosion, or significant bleeding. Eighty-three percent of
atients had no adverse events judged probably or definitely related to the device.
atients experienced significant improvement in health-related quality of life, al-
hough the physiologic and exercise outcomes did not show statistically significant
mprovements.
onclusions: These first multicenter results with the Intrabronchial Valve demon-
trate significant improvements in health-related quality of life and acceptable
afety, ease of use, and procedural complication rates. The valve might be a safer
nd less-invasive alternative to surgical therapy for patients with severe emphy-
ema.
mphysema affects 2 to 3 million persons in the United States and is
characterized by progressive deterioration in pulmonary function, with ex-
ercise limitation, disabling dyspnea, and an inexorable decrease in quality of
ife. Until recently, surgical palliation of the symptoms of emphysema was only
sed for the very small subset of patients with giant bullae. Lung transplantation was
ntroduced as an option for patients with end-stage emphysema in the 1980s, but it
s only offered to the most severely ill patients who have minimal comorbidity and
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TSounger age. The number of transplantations performed is
urther limited by a shortage of lung donors, with only
pproximately 400 patients with emphysema per year
0.013%) undergoing transplantation.1 Lung volume reduc-
ion surgery (LVRS) was reintroduced in the early 1990s
nd has had its efficacy investigated more thoroughly than
erhaps any other new surgical procedure. LVRS improves
ulmonary function, exercise capacity, and quality of life in
elected patients with severe chronic obstructive pulmonary
isease (COPD) and emphysema, but it has demonstrated
ajor limitations.2 First, the benefit of LVRS is limited
arrow subsets of patients with certain patterns of emphy-
ema and with minimal comorbidity.2 Second, patients un-
ergoing LVRS have significant risk of morbidity that can
xtend the period of convalescence before they can re
he desired clinical improvement or that might prevent
enefit from LVRS at all.3
The goal for future developments in the treatment of
dvanced emphysema would be to provide similar benefit as
VRS, with less risk, shorter recovery, and decreased cost.
ndobronchial occlusion with a plug or valve might be able
o produce targeted areas of atelectasis and subsequent lung
eduction with similar physiologic and functional outcomes
o LVRS. Alternatively, valve occlusion of the airways
ight have effects that differ from LVRS, such as the ability
o decrease dynamic hyperinflation, work of breathing, and
yspnea with exertion. The Intrabronchial Valve (IBV; Spi-
ation, Inc, Redmond, Wash) is a novel implantable device
esigned as a one-way valve that is placed by means of
exible fiberoptic bronchoscopy. The IBV obstructs airflow
nto targeted bronchopulmonary segments and in unpub-
ished animal model studies appears to allow drainage of
istal air and mucus. This report describes the initial pilot
uman study results with the IBV to determine feasibility
nd safety data before proceeding to a larger pivotal clinical
rial.
aterials and Methods
his prospective, open-enrollment, multicenter cohort study en-
olled patients with heterogeneous, upper lobe–predominant em-
hysema, and severe COPD (Table E1). Patients excluded 
he trial were those already accepted and listed for LVRS or lung
ransplantation, those defined as high risk within the National
mphysema Treatment Trial (NETT),4 those having a significan
Abbreviations and Acronyms
COPD chronic obstructive pulmonary disease
IBV  Intrabronchial Valve
LVRS  lung volume reduction surgery
NETT  National Emphysema Treatment Trial
SGRQ St George’s Respiratory Questionnaireronchospasm, or those with chronic bronchitis and heavy sputum f
6 The Journal of Thoracic and Cardiovascular Surgery ● Januaroduction. Screening studies were similar to those used by the
ETT,5 including baseline physiologic, radiologic, and quality-
ife testing. Patients were required to fulfill a pulmonary rehabil-
tation program or complete more than 140 m in a 6-minute walk
est. The clinical protocol was reviewed and approved by each
nvestigating site’s institutional review board and monitored by an
versight data safety monitoring board. All patients provided in-
ormed consent for the procedures, data collection, and participa-
ion in the clinical trial.
The IBV is an implantable device designed for placement in the
egmental or subsegmental bronchi by means of flexible bronchos-
opy (Figure E1). The valve is made of a nitinol framework
alve’s 5 distal anchors provide stability and allow distal seating of
he valve into the airway without perforation. The proximal portion
s made up of 6 support struts that are covered by a synthetic
olyurethane polymer. The membrane-covered struts expand radi-
lly and form an umbrella shape that allows conformation and
ealing to the airways with minimal pressure on the mucosa. The
alve is designed to limit distal airflow, yet the membrane and
upport struts should allow air and mucus to flow out of the
ccluded segment by compressing the umbrella. The valve design
ncludes a proximal center rod that allows early repositioning or
emoval.
Patients underwent general anesthesia with endotracheal intu-
ation. Therapy generally consisted of bilateral occlusion of all
pper lobe segments except for the lingula, with placement of
alves into segmental airways, subsegmental airways, or both to
cclude all planned segments. Airways were sequentially sized
ith a calibrated balloon to determine valve size. Available valve
iameter sizes were 4, 5, 6, and 7 mm. For segments with a
iameter of greater than 7 mm, subsegmental orifices were mea-
ured to define subsegmental valve size.
The IBV was deployed by means of flexible bronchoscopy with
different delivery systems. The direct-load system provided a
oading kit that allowed the valve to be compressed and loaded
etrograde into the 2-mm working channel of the bronchoscope
Figure E2, A). In the direct-load configuration the tip of 
ronchoscope was inserted into the orifice to be occluded, and the
ip of the scope was positioned at the desired depth of the valve
nchors. The IBV deployment tool was used to advance the valve
ut of the working channel. When the anchor tips extruded and
ontacted the bronchial wall, the bronchoscope was withdrawn
hile continuing to deploy the valve until it was fully delivered out
f the bronchoscope.
The catheter-load system compressed the valve into a 2.2-mm
exible delivery catheter with an integral deployment rod (Figure
2, B). The catheter was then placed through the working channel
2.6 mm) of the flexible bronchoscope and directed into the
argeted airway. The valve was visualized through the clear sheath
f the delivery catheter and positioned so that the top of the valve
embrane and struts was at the level of the desired position in the
irway. The valve was then deployed, the position was assessed,
nd adjustments were made as necessary. The catheter shaft was
evised for the last 8 patients to prevent stretching and nondeploy-
ent of the valve. Before the catheter revision, the direct-load
echnique was the dominant method used.
Valves were deployed in all planned segments or subsegments,ollowed by a final visual inspection. The patient was then extu-
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TSated and managed on a surgical/medical inpatient floor for stan-
ard postanesthesia COPD management, which included the use of
ronchodilators and supplemental oxygen. Patients had a chest
adiograph taken immediately after the procedure and each day of
npatient hospitalization. Prophylactic antibiotics and periopera-
ive steroids were used at the discretion of the investigating phy-
ician. For the first 19 procedures, the protocol required hospital-
zation and observation for a minimum of 2 postprocedure days.
ecause patients typically had no obvious need for hospitalization
n the second day after the procedure, the protocol-required stay in
he hospital was decreased to a minimum of 1 postprocedure day.
Patients were asked to keep a symptom and medical history
iary. The patients were evaluated at 1 to 2 weeks after discharge
rom the hospital with a history, physical examination, chest
adiograph, and resting oxyhemoglobin saturation measurement.
t 1 month after valve placement, patients had another follow-up
isit and testing. The patients then underwent a second bronchos-
opy procedure after either topical anesthesia with conscious se-
ation or general anesthesia was obtained. The implanted valves
ere inspected for evidence of tissue erosion, migration, and
ppropriate seal of the membrane against the airway wall and to
ssess for signs of complications, including purulence or granula-
ion tissue. During this bronchoscopy, valves could be removed,
emoved and replaced, or added, as determined by the investigator.
f new valves were inserted, the patient underwent general anes-
hesia, hospitalization, and follow-up similar to the initial
rocedure.
Patients returned for follow-up evaluation by the investigators
t 3-, 6-, and 12-month intervals. Chest radiographs were analyzed
t each visit to document the stability of the valve position. The
nvestigators assessed intervening adverse clinical changes for
heir seriousness and any possible relationship to the device.
A panel of experts, investigators, and Spiration, Inc, personnel
etermined a priori adverse event definitions. A clinical events
ommittee adjudicated all adverse events for severity and relation-
hip to the device. The primary end point of the pilot study was
afety, as measured by the incidence of migration, erosion, and/or
ABLE 1. Baseline and demographic data
Mean  SD n
ge (y) 64 10 3
ale/female sex 19/11
EV1(L) 0.86 0.28 3
VC (L) 2.57 0.79 3
LC (L) 7.74 1.53 2
V (L) 5.10 1.20 2
LCO 10.50 4.01 2
aO2 70.56 8.37 2
aCO2 41.58 5.47 3
MWD (m) 334.06 109.42 3
ork (W) 43.80  24.76 2
GRQ total scores 59.7 13.7 2
D, Standard deviation; FEV1, forced expiratory volume in 1 second; FVC, fo
apacity of lung for carbon monoxide; 6MWD, 6-minute walk distance;
uestionnaire.nfection related to the device. Other safety measures included t
The Journal of Thoracneumothorax requiring a chest tube for more than 7 days, hospital
ength of stay beyond that required by the protocol, additional
rocedures required because of adverse events, COPD exacerba-
ions, persistent cough, bronchitis or pneumonia, respiratory fail-
re, hemoptysis requiring intervention, and death.
Three variables were identified prospectively as pilot study
easures for efficacy: an increase in posttreatment forced expira-
ory volume in 1 second (FEV1) of 15% or greater, an increase of
-minute walk distance of 15% or greater, or an improvement in
he St George’s Respiratory Questionnaire (SGRQ) total score of
ore than 4 points. These thresholds for minimal clinically im-
ortant differences were based on published literature.6-8 Other
easures of efficacy included decrease in oxygen supplementation
equirements, improvement in Medical Outcome Study Short-
orm Health Survey (SF-36) scores, and improvement in the
odified Medical Research Council dyspnea score. Dyspnea and
eneral health-related quality of life were assessed with question-
aires that were provided onsite or through the mail. All question-
aires were completed during periods of clinical stability.
Descriptive data are expressed as means  standard deviation,
edians, and 95% confidence intervals. Categoric data are ex-
ressed as counts and proportions. Mean scores before and after
alve placements were compared by using the Wilcoxon signed-
ank test. A P value of less than .05 was considered statistically
ignificant, and comparisons for multiple tests were not used.
piration, Inc, assisted in data collection and collation and pro-
ided an independent consultant for statistical analysis.
esults
hirty patients were treated at 5 clinical centers from Jan-
ary through July 2004 (Table 1). Patients had sever
ery severe airflow obstruction, with air trapping, thoracic
yperinflation, and a reduced diffusing capacity of lung for
arbon monoxide value. All patients had bilateral upper
obe treatment. The average initial procedure time was 65
3 minutes (range, 15-125 minutes). The average time for
Range Percent predicted (mean  SD)
42-78
0.40-1.75 31.00  9.40
1.34-4.44 70.40  16.89
4.97-10.50 134.24  24.18
3.07-7.32 246.52  60.30
4.81-20.60 42.71 13.02
53-84 —
29-55 —
91-509 —
1-116 —
32.3-86.6 —
vital capacity; TLC, total lung capacity; RV, residual volume; DLCO, diffusing
, maximum work on a cycle ergometer; SGRQ, St George’s Respiratory0
0
0
9
9
8
8
0
0
8
9
rced
Workhe last 8 procedures (with the modified catheter) was 41
ic and Cardiovascular Surgery ● Volume 133, Number 1 67
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G
TS inutes. There were 184 valves in place at completion of
he initial procedure and 194 valves after the completion of
he 1-month bronchoscopy, for an average of 6.5  1.6
alves (range, 5-10 valves) per patient. The airways treated
ere 166 (73%) segmental airways and 62 (27%) subseg-
ental airways. When 1 valve treated 2 segmental airways,
t was counted as 2 segments treated. The 7-mm valves were
sed in 69% of the instances, with 6 mm at 27% and 5 mm
t 4%, and only one 4-mm valve was placed. Successful
alve placement was accomplished in all but 2 of the
ttempted sites (99%) at the first procedure, and all desired
ites were treated after the second procedure. The 2 loca-
ions not initially treated were the anterior subsegments of
he upper lobes of each lung, where the angle did not allow
cope entry for direct-load placement. The 1-month bron-
hoscopy resulted in revisions in 17 patients with removal
f 8 valves, replacement with 16 valves, and placement of
5 additional valves in new segments or subsegments. Rea-
ons for valve revisions at 1 month were visual judgment
hat valves were angulated or too distal in an airway, re-
ulting in incomplete contact between the membrane and an
irway wall. Sometimes 1 segmental valve was removed
nd replaced with 2 subsegmental valves. In most cases
alves were added for additional treatment.
All patients were extubated at the end of their procedure.
he median hospital length of stay after the procedure was
days. The initial protocol required 2 days of postprocedure
bservation, which was later modified to only 1 day. Pa-
ients typically stayed in the hospital only for the protocol-
equired length of stay. However, 2 patients were dis-
harged after 3 days. One patient remained hospitalized
ntil transportation needs were addressed. One patient had a
3-day admission. After an uneventful procedure, the pa-
ient experienced chest pain, wheezing, and acute respira-
ory distress, which resulted in a cardiopulmonary arrest.
he patient survived with a myocardial infarction. He later
ad a second arrest and experienced nosocomial pneumo-
ia. All valves were removed 21 days after the original
rocedure. Follow-up 8 months after the initial valve place-
ABLE 2. Complications and thoracic events in the first 6
eriprocedure
ronchospasm 4* 6%* CO
rrhythmia, cardiovascular 6 9% B
aCO2 retained 2 3%† D
yspnea 1 1% Th
emoptysis 1 1% H
Pn
ee text for definitions. COPD, Chronic obstructive pulmonary disease. *N
n 1 patient. ‡None in the area of Intrabronchial Valve treatment.ents showed a return to baseline, with no evidence of i
8 The Journal of Thoracic and Cardiovascular Surgery ● Januadverse effects from valve implantation. One patient with-
rew from the study before 6-month data collection because
f the rigor of testing, and another withdrew at 8 months
ecause of lack of response. Two patients withdrew at 7 and
months, respectively, for valve removal and anticipated
VRS.
Twenty-eight patients have been followed for at least 6
onths after valve placement. Data are currently available
n 6 patients at 12 months. Because the protocol and IBV
esign allows removal, 7 patients (48 valves) underwent late
alve removal within the study period. Reasons for late
alve removal were LVRS (2 patients) at 7 and 9 months,
neumonia in the area of valves (2 patients) at 9 and 12
onths, and nonresponders who requested removal (3 pa-
ients) at 3, 5, and 8 months. Only 1 valve in a patient
lecting LVRS was not removed (1/48 [2%] valves) because
f inadequate visualization and difficult access. Several
ore valves were difficult to visualize because of hyper-
lastic tissue, but these were removed with the aid of
uoroscopy.
On the basis of the judgment of the investigator and
djudication by the clinical events committee, no adverse
vents were definitely attributed to the valves. There were 6
vents in 5 (17%) patients judged probably related and 20
vents in 12 (40%) patients judged possibly related to the
evice. Fifty events were judged definitely not or probably
ot related. There were no unanticipated serious adverse
vents. Two patients experienced 5 anticipated serious ad-
erse events, 3 events in the patient described above and
neumonia and a COPD exacerbation (at 22 and 53 days)
hat each required hospitalization in another patient. Spe-
ifically, valve erosion, migration, severe hemoptysis, and
eath did not occur. Device-, procedure-, or anesthesia-
elated events did occur in up to 9% of the procedures
Table 2). The most frequent event was cardiovascular, 
combination of arrhythmias, hypotension, or hyperten-
ion. Table 2 shows the occurrence of events on the p
ure day and until discharge (periprocedure), after discharge
nd before 30 days, and from 30 days to 6 months after the
ths
to 30 d after valve implantation
30-180 d after valve
implantation
flare 4 6% COPD flare 4
itis 3 4% Bronchitis 4
a 3 4% Dyspnea 3
Pain 2 3% Thorax Pain 1
tysis 1 1% Hemoptysis 1
onia 4 6%‡
r of episodes and proportion of total procedures (n  66). †Two episodesmon
Up
PD
ronch
yspne
orax
emop
eum
umbenitial procedure.
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G
TSThe only consistent evidence of efficacy was docu-
ented by the SGRQ. There were significant changes in the
GRQ scores at all postprocedure time points compared
ith the preprocedure baseline (Table 3). The mean ch
t 6 months was 6.8  14.3 points. Fifty-two percent of
he patients had a clinically meaningful response (SGRQ
core improved by at least 4 points) at 6 months after
alve implantation. The NETT used a more stringent
hange (SGRQ score improved by greater than 8 points),
nd 39% of patients receiving LVRS in this trial met these
riteria at 6 months. The other measures of efficacy before
nd after valve implantation are shown in Table E2.
nly statistically significant changes occurred in health-
elated quality of life.
iscussion
he results of several large cohort studies and randomized
rials have firmly established the benefit of LVRS for pal-
iating symptoms in select patients with emphysema.2,3,9-14
owever, LVRS has 2 major limitations that affect its
pplicability to many patients with emphysema. First,
VRS is indicated in only a fairly narrow subset of patients
ased on pattern of disease and several exclusionary comor-
idities.2 Second, LVRS is a major operative procedure
high-risk patient population, with its attendant morbidity
nd mortality. Patients undergoing LVRS can anticipate a
ostoperative mortality of 5.5%, major pulmonary morbid-
ty of 30%, and cardiac morbidity of 20%.3 Patients spend
ignificant time recovering after LVRS, with nearly 30% of
atients still hospitalized or in rehabilitation facilities 1
onth postoperatively and 15% still not at home 2 months
fter the operation.2 Attempts to minimize surgical morbi-
ty from thoracotomy or median sternotomy with minimally
nvasive thoracoscopic LVRS have not shown any differ-
nce in the incidence or profile of complications.15
Within 3 to 4 years after the reintroduction of LVRS,
everal investigators proposed a variety of bronchoscopic
echniques to treat patients with emphysema and
OPD.16-22 Some of the pilot studies of segmental air
ABLE 3. Health-related quality-of-life, FEV1, and 6MWD c
GRQ total scores
hange compared with baseline, mean  SD (P value) 
roportion with change 4 points
roportion with change 8 points
EV1
roportion with change 15%
MWD
roportion with change 15%
EV1, Forced expiratory volume in 1 second; 6MWD, 6-minute walk distanbstruction with 1-way endobronchial valves have been 3
The Journal of Thoracble to show improvement in FEV1, exercise capacity, or
uality of life, although the patient numbers are small, and
he results are variable. Endobronchial valve placement has
een well tolerated, with complications of pneumothorax in
5% to 25% and few reports of bronchospasm or obstruc-
ive pneumonia. Reported in-hospital length of stay for the
ilot endobronchial valve studies has been 6 to 10 days19-22
The IBV was designed as a 1-way valve to limit airflow
nto the distal bronchopulmonary segments in an effort to
chieve lung volume reduction, reduction of dynamic hy-
erinflation, and other physiologic changes, with subse-
uent improved functioning, lessened dyspnea, and im-
roved quality of life. The valve has been successfully
emoved in animal studies at periods ranging from a
ays to 12 months.23 This design benefit is important 
nitial safety and possible efficacy, allowing valves to be
emoved and repositioned for optimal effect and allowing
alve removal for any early valve-related complications.
This pilot clinical trial is, to date, the largest published
xperience with bronchoscopic approaches to emphysema
nd the first with results beyond 3 months. Valve implan-
ation was technically straightforward, with short procedure
imes even across multiple bronchoscopists and multiple
linical centers. In this initial clinical experience placement
f valves was successful in all desired segments and sub-
egments. Valves were able to be easily adjusted, removed,
r replaced at the initial and follow-up procedures. Al-
hough intended as permanent implants, valves were able to
e removed up to 12 months after implantation. Early and
ate reversibility of the procedure has not been previously
ddressed in the endobronchial lung reduction literature but
as important implications in the event of adverse events
elated to the valve or an elective decision to remove the
alves if there is an absence of clinical benefit.
This clinical trial had a protocol-driven hospital stay of 2
ostprocedure days and, later, 1 postprocedure day. Most
atients were hospitalized only because of protocol require-
ents, with a median hospital stay of 3 days (90%), com-
aring favorably with earlier series with hospital stays 2 to
es and proportion responding
1 mo 3 mo 6 mo
n  27 n  28 n 23
9.6 (.0001) 6.9  12.9 (.01) 6.8  14.3 (.05)
7 (63%) 16 (57%) 12 (52%)
1 (41%) 10 (36%) 9 (39%)
n  29 n  28 n  26
3 (10%) 5 (18%) 2 (8%)
n  28 n  27 n  25
8 (29%) 3 (11%) 6 (24%)
GRQ, St George’s Respiratory Questionnaire; SD, standard deviation.hang
8.1 
1
1times as long. There were very few hospital or 30-day
ic and Cardiovascular Surgery ● Volume 133, Number 1 69
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G
TSomplications and no serious late valve-related complica-
ions, confirming a very high safety profile. Specifically,
here were no instances of pneumothorax, obstructive pneu-
onia, intractable cough, or valve dislodgement in the first
months. Our clinical experience suggests that endobron-
hial treatment of emphysema with the valve can likely be
erformed as an outpatient procedure in the future because
f the high degree of procedure safety and good patient
olerance. This is important from a public health and cost-
ffectiveness perspective. Surgical lung volume reduction,
ven in the most select subgroup with low exercise toler-
nce after rehabilitation and heterogeneous upper lobe dis-
ase, has an estimated cost of approximately $100,000 per
uality-adjusted life-year, with much of this cost a result of
he initial hospitalization.24
The current trial was not designed to establish effective-
ess, although data were collected to provide guidance for
he design of a larger randomized pivotal trial. In this study
alve placement did not produce significant changes in
EV1, lung volume, alveolar gas exchange, or exercise
apacity. In contrast, significant improvements were found
n disease-specific quality of life, as measured by the
GRQ. One possible explanation is that these patients
chieved a placebo effect as a benefit of having an inter-
ention in a clinical trial. However, placebo effects on the
GRQ within a pharmacology trial showed an improvement
f only 4 points,25 and experts have suggested that place
ffects diminish over time. The mean improvement at 1
onth in this series was greater than 8 points, and this was
ustained at 6 months, which is suggestive of a true treat-
ent effect not captured by the common spirometry, lung
olume, alveolar gas exchange, or exercise measures.
Although the original goal of endobronchial therapies
as been to mimic surgical lung reduction by promoting
telectasis in treated segments, the achievement of this goal
as been sporadic in previous reports and was noted only a
ew times in this study (data not shown). Although atelec-
asis is achieved in animal studies, this appears harder to
chieve in the setting of collateral ventilation in patients
ith end-stage emphysema. There are several possible
echanisms of action that might explain the improvement
f patients in our series. Valve placement in the more severe
egments might help to redirect ventilation to better-
erfused segments and improve ventilation-perfusion
atching and symptoms without seeing an obvious spiro-
etric or lung volume effect. The other mechanism of
mprovement can be seen only with exercise because of a
ossible treatment effect on dynamic hyperinflation.26 Dur-
ng exercise, increased respiratory rate can lead to increased
ir trapping, particularly in areas with worse emphysema
nd high compliance, ultimately increasing lung volumes
nd worsening exercise tolerance and dyspnea. Endobron-
hial occlusion might help to mitigate dynamic hyperinfla-
0 The Journal of Thoracic and Cardiovascular Surgery ● Januaion during exercise and improve symptoms without show-
ng improvements in resting pulmonary function.
The patient’s primary motives for seeking palliative ther-
pies for end-stage emphysema are to improve symptoms,
unctioning, and health-related quality of life.27 This study
howed overall improvement in disease-specific quality of
ife, whereas only a subset of patients showed improvement
n lung function or exercise capacity. In addition to seeing
mprovements in health-related quality of life, investigators
ish to see improvement in more objective measures, such
s FEV1 and exercise capacity, which might or might not
unction as surrogates for quality of life.27 Two recent
andomized controlled trials of LVRS have focused on a
uality-of-life end point as a primary outcome.10,11 Tar-
eted endobronchial occlusion of upper lobe segments in
atients with emphysema can be achieved with very high
uccess and low morbidity and might provide palliation of
ymptoms for some patients. Endobronchial therapies for
mphysema can create treatment options for patients not
urrently considered candidates for LVRS and might offer
ess morbidity and more acceptability for LVRS candidates.
urther studies need to concentrate on quality of life as the
undamental end point and try to establish the important
echanisms of improvement.
We thank Yi-Jing Duh, PhD, for statistical computations; Bill
irokman for data compilation; and Vickii Wyttenbach for manu-
cript preparation assistance.
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iscussion
r John D. Mitchell (Denver, Colo). Doug, I want to congratulate
ou and your coinvestigators on this very nice study, article, and
resentation. Two of the biggest problems with surgical LVRS are
he attendant morbidity and mortality associated with the proce-
ure and the cost. One would hope that the development of
ess-invasive endobronchial therapies, such as this valve, could
ead to expansion of the subgroup of patients with emphysema
ho might benefit from LVRS with less risk and at a lesser cost.
I just have a couple of questions for you. First, I wonder
hether you could comment on some of the technical aspects of
alve implantation. Is general anesthesia necessary? Are some
egments and subsegments harder to instrument than others? And
s this what led to considerable variation or range of the procedure
imes seen in the study?
Dr Wood. In terms of the first part of that question, general
nesthetic is probably not necessary. We chose to use general
nesthesia in this initial experience to decrease the possible tech-
ical difficulties and variability of doing this in an awake patient.
ll that said, I think that even later, as we gain experience, there
till might be some benefit of doing it with a general anesthetic.
here is a lot of airway manipulation of multiple segments, and it
s very easy to do with a patient anesthetized. I think that the aspect
f cough or respiratory movement might make some of those
djustments and placement of the valve more difficult. I do not
ave experience with that yet, but I can anticipate that that might
e the case.
In terms of segments that are more difficult: yes, there are. As
ou get more acute angles into the anterior segments of both upper
obes, those can sometimes be difficult angles to achieve. Fortu-
ately, the fact that we have a delivery catheter that goes through
he flexible bronchoscope and can be visualized going into that
egment does make it easier and that has become easier, for
xample, in the last 8 patients, as I describe. Still, sometimes the
ngles are difficult in the anterior segments.
Does that relate to the variability in procedure time? Possibly.
am not sure. I think that obviously this is an initial experience,
nd therefore the investigators as they were first doing this were
ompletely new to the procedure, so that this involves all of the
earning curve of doing the procedure as well, which I think we
ave gotten better at, but I think we would have to have substan-
ially more experience to know whether we can decrease that time
eliably.
Dr Mitchell. Second, were you surprised at the relative lack of
omplications caused by the valves? Specifically, I am interested
n either valve migration or postobstructive pneumonia.
Could you comment on the hyperplastic tissue response that
as seen associated with some of the valves several months aftermplantation?
ic and Cardiovascular Surgery ● Volume 133, Number 1 71
I
s
s
t
b
o
p
v
i
f
i
s
L
h
F
t
h
n
q
d
a
t
f
T
t
o
l
N
t
p
d
d
h
b
r
s
i
e
i
e
i
i
m
c
d
g
a
s
t
o
i
y
u
p
m
i
t
w
t
l
p
a
p
T
m
a
n
b
b
f
p
o
p
p
1
m
h
o
t
b
p
v
T
b
p
w
s
b
p
y
t
t
h
l
d
s
d
t
w
General Thoracic Surgery Wood et al
7
G
TSDr Wood. That is a good question. I am somewhat surprised.
expected first of all an instance of pneumothorax, which has been
een in similar trials of the Emphasis valve. They have had a
ignificant incidence of pneumothorax, which we did not have in
his initial phase A of our pilot trial, but I would have expected a
ig concern in plugging the airways of a patient with COPD as
pposed to obstructive pneumonia. The valve is obviously pur-
osely designed to allow mucus secretions to pass proximal to the
alve, yet still it is functionally obstructed, and I would expect an
nstance of postobstructive pneumonia distal to these valves that,
ortunately, we did not see. With additional time, we might.
In terms of the hyperplastic tissue, I have now removed valves
n 2 of my patients out 1 year because they have not had a
ubstantial improvement and now wanted to be considered for
VRS, and we wanted to remove the valves before that. They have
ad variable amounts of hyperplastic tissue obscuring the valves.
ortunately, we still have been able to remove all valves—100% of
he ones that I have done even at 12 months—but some of them do
ave hyperplastic tissue proximal to the valve.
Dr Mitchell. Third, you were able to report that a substantial
umber of patients had a meaningful change in their health-related
uality of life comparable with that seen in the NETT. When you
id that comparison, did you use patients in the NETT with similar
natomic findings to those in your study?
Dr Wood. No, and it is not really possible to do that because
hat requires access to the primary data, which are not yet released
or the NETT, to be able to try to stratify it to that degree.
herefore this is just a general NETT population.
Dr Mitchell. Finally, as I mentioned before, it would be nice if
he use of these less-invasive technologies could expand the pool
f patients with emphysema eligible for LVRS. In this study you
imited your patient population to those who met generally the
ETT criteria and had upper lobe–predominant disease, perhaps
he group that you would expect to have the best outcome from this
rocedure. Could you comment or maybe speculate how this
evice might work in those with non–upper lobe disease, those
eemed high risk by NETT criteria, perhaps even those with
omogeneous disease and those with significant medical comor-
idities?
Thank you very much. I enjoyed the article.
Dr Wood. Thank you, John. In terms of speculation and the
eason for selecting this most favorable subset as an initial pilot
eries, you can probably understand the desire to do that when your
nitial study is a safety study looking at feasibility more than
ffectiveness. That is the reason for the stringent selection criteria
n this phase. You are right that if in this phase it proves to be
ffective and a pivotal trial, then I think we should expand the
ndications and look at patients who otherwise might have contra-
ndications to LVRS, as I introduced at the beginning of this, who
ight benefit from this or other forms of endobronchial therapy.
Dr Jerome McDonald (Lakewood, Wash). One of my con-
erns about this particular procedure over LVRS is that you have
eveloped an obligate shunt, and I was wondering whether there is
oing to be any assessment in your future trials of efficacy with
ny perfusion studies or any way to assess whether an obligate
hunt is going to decrease some of the effectiveness or efficacy of
he procedure. t
2 The Journal of Thoracic and Cardiovascular Surgery ● JanuaDr Wood. In fact, most likely what has happened is the
pposite of what you are talking about, which is an improvement
n ventilation-perfusion match rather than a worsening. In fact, if
ou look at these patients, they have such low compliance in their
pper lung fields that they are preferentially ventilated but very
oorly perfused. Therefore, in fact, one of the ways that valves
ight be effective in improving patient quality of life is actually by
mproving ventilation-perfusion mismatch by decreasing the ven-
ilation in an area that is already underperfused.
Dr Donald Low (Seattle, Wash). Doug, I enjoyed the article. I
ould specifically like to ask you a question regarding something
hat is in your abstract regarding follow-up bronchoscopy. It looks
ike that was a routine aspect of your ongoing assessment in these
atients. I would like you to just let us know when this was done,
nd interestingly, I note that 17 patients—more than half of your
atients—either had valve revision or additional valves placed.
he valve revision issue is interesting considering how low your
igration or other problems were. Could you tell us a little bit
bout what that valve revision was all about and what indicated the
eed for additional valves in selected patients on the follow-up
ronchoscopy?
Dr Wood. Very astute of you, Don. I actually left that out
ecause of lack of time, but in fact the protocol required a 1-month
ollow-up bronchoscopy that we wanted to do to assess valve
lacement and adequacy of seating of each of the valves and lack
f migration, so that was a part of the planned protocol. All
atients had a follow-up bronchoscopy at 1 month. Of the 30
atients, 17 of them had some revisions of their valves at that
-month planned bronchoscopy. Some of them had valves re-
oved. Some of them had valves removed and replaced, and some
ad additional valves placed. The most common rationale for each
f them was not any valve migration but an appearance of a valve
hat looked like it might not be occlusive because of angulation or
ecause of a wrinkle in the valve membrane that we thought could
ossibly be improved by a different size or better seating of the
alves, and therefore those valves were removed and replaced.
hat was the most common indication. The reason for new valves
eing placed is sometimes that we were cautious in the initial
lacement and did not necessarily occlude every segment that we
ould like to and with more confidence would treat additional
egments at the second bronchoscopy. Actually, after the second
ronchoscopy, there were 10 more valves than the 184 that I
resented in the article here.
Dr Henning Gaissert (Boston, Mass). I very much enjoyed
our presentation, Doug. In other areas of the airway, when pros-
hetic devices are being placed, it is not necessarily clinical infec-
ion but colonization with particular organisms that indicate a
igher risk of long-term infection, these organisms being particu-
arly Staphylococcus aureus and Pseudomonas species. Have you
one any culturing of the airway to see whether you get these
pecific organisms?
Dr Wood. No, we have not.
Dr Gaissert. Thank you. I very much enjoyed it.
Unidentified speaker. Nicely done, Doug. As to volume re-
uction surgery, one of the ways it works is it reduces the size of
he lungs and mechanics improve and so on. Do you have any idea
hether you are actually reducing the size of these lungs withhese valves? Do you see it?
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G
TSDr Wood. The answer to that is, at least in this pilot experience
ith the first 30 patients, no. We are not reducing the size of the
ungs, and that is kind of what my next-to-last slide was about. We
ave different mechanisms working here than mechanisms that we
hought were going to be working when we try to duplicate LVRS.
learly the patients are having an improvement in quality of life,
ut the objective measures that we have used in LVRS are not
ecessarily representing the reason that these patients are having
n improvement. It might be things like dynamic hyperinflation. I
ill say just as a teaser that we have moved into a second phase of
his study already and with a slightly different valve design and
ome more aggressive treatment, and in that group we are starting
o see volume reduction as well with the atelectasis that we would
ind of like to see. Surgically what we were thinking that we were
iming for is an atelectasis developing in the upper lobes to mimic
he effects of LVRS, but at least in these first 30 patients, that was
ot seen to any reliable degree.
Dr Joseph Shrager (Philadelphia, Pa). Doug, how is it that
hese did not have surgical LVRS? In other words, did they have
o be assessed by a surgeon or decline having surgical LVRS,
iven that you have a proved therapy and now have an experi-
ental therapy?
Dr Wood. It is a good question. Some of these patients wereThe Journal of Thoracprevious coronary artery bypass graft and was not a candidate
or LVRS but would very much be a candidate for an endo-
ronchial therapy. Other patients were candidates for either,
nd they were all in centers that could do LVRS, obviously in
urgical centers like ours. They were all counseled about the
hoices of LVRS or involvement in this clinical trial. At the
ther centers, with the pulmonary physicians as principal in-
estigators, there was the same counseling. The effort was to
rovide patients with counseling about all of their options,
ncluding surgical volume reduction.
Dr Shrager. The other issue is, can you speculate about
hy—you touched on this a little bit—the FEV1 is not im-
roved, whereas the quality of life is improved?
Dr Wood. Well, the FEV1 surprisingly was not improved
here quality of life was and that is where I think our dilemma
s, except we know that FEV1 is not a reliable surrogate for
mprovement after LVRS either, with a substantial number of
atients having much more significant improvement in their
unctional capacity and quality of life that is not well repre-
ented by FEV1. Our problem is that we are not yet very good
t measuring the right measurement, and FEV1 is common, so
e use it a lot, but it is not a very reliable measure of efficacyot candidates for LVRS. For example, one of my patients had in these types of treatments for emphysema.
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TSABLE E1. Inclusion and exclusion criteria
nclusion criteria
● Age 18 y
● Severe, heterogeneous, predominately upper lobe emphysema
● Ability to meet goals of a comprehensive pulmonary rehabilitation program
● 6-min walk of 140 m (459 ft)
● Can complete 3-min unloaded pedaling in exercise tolerance test
● PFTs
● FEV1 45% of predicted value (15% of predicted value if age 70 y)
● TLC 100% of predicted value
● RV 150% of predicted value
● Arterial blood gas
● PaCO2 50 mm Hg
● PaO2 45 mm Hg on room air
● No coexisting medical problem that would preclude bronchoscopy
● If female with childbearing potential, negative pregnancy test result within 7 days before procedure
● Willing to undergo bronchoscopy and follow-up
● Ability to provide informed consent
xclusion criteria
● FEV1 20% of predicted value with DLCO 20% or homogeneous emphysema
● Active asthma, chronic bronchitis, or clinically significant bronchiectasis
● Smoking within 4 mo
● History of recurrent infections with clinically significant sputum production
● Giant bulla (greater than one-third volume of lung)
● Pulmonary arterial hypertension (peak systolic pulmonary artery pressure 45 mm Hg)
● Requires 6 L/min O2 to keep SpO2 89%
● Significant comorbidity
FTs, Pulmonary function tests; FEV1, forced expiratory volume in 1 second; TLC, total lung capacity; RV, residual volume; DLCO, diffusing capacity of lung
or carbon monoxide; SpO2, arterial oxygen saturation.
ABLE E2. Quality of life, lung function, gas exchange, and exercise tolerance before and after valve placement (mean 
D)
Baseline (n) 1 mo (n) 3 mo (n) 6 mo (n)
EV1 (L) 0.86 0.28 (30) 0.87 0.29 (29) 0.89 0.31 (28) 0.83 0.32 (26)
LC (L) 7.74 1.53 (29) 7.75 1.47 (29) 7.94 1.27 (28) 7.75 1.27 (25)
V (L) 5.10 1.20 (29) 5.04 1.16 (29) 5.28 1.09 (28) 5.07 0.88 (25)
LCO (mL min1 mm Hg1) 10.50 4.01 (28) 10.43 4.20 (29) 10.96 4.3 (28) 11.07 4.29 (25)
aO2 (mm Hg) 70.6 8.4 (28) 72.9 9.0 (28) 72.1 10.6 (27) 71.7 10.4 (24)
aCO2 (mm Hg) 41.6 5.5 (30) 41.9 6.5 (28) 42.0 6.2 (27) 43.3 7.4 (25)
rescribed O2 (L/min) 1.12 1.6 (30) 0.98 1.1 (28) 1.07 1.3 (27) 0.88 1.1 (25)
MWD (m) 334 110 (30) 329 114 (28) 330 125 (27) 360 113 (25)
xercise max (W) 43.8 24.7 (28) 41.3 22.4 (28) 40.6 19.3 (26) 40.2 23.2 (24)
MRC 1.9 1.0 (26) 2.0 0.7 (27) 1.9 1.0 (25) 1.9 1.0 (23)
F-36, physical composite score 32.9 7.1 (28) 35.1 8.1 (27) 33.5 7.2 (28) 35.2 8.9 (25)
F-36, physical function 25.3 18.6 (29) 31.9 21.3 (27) 28.0 17.8 (28) 33.2 21.7 (25)
GRQ total score 59.7 13.7 (29) 52.7 14.4 (27) 53.7 13.0 (28) 54.8 14.6 (23)
D, Standard deviation; FEV1, forced expiratory volume in 1 second; TLC, total lung capacity; DLCO, diffusing capacity of lung for carbon monoxide; 6MWD,
-minute walk distance; MMRC, modified Medical Research Council dyspnea score; SF-36, Medical Outcome Study Short-Form Health Survey; SGRQ, St
eorge’s Respiratory Questionnaire.
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TSigure E1. A, Intrabronchial Valve appearance and nomenclature.
, Intrabronchial Valve in an airway, as viewed with a flexible
ronchoscope.The Journal of Thoracicigure E2. A, Direct-load delivery. The compressed valve is
oaded into the distal end of the working channel in the flexible
ronchoscope and extruded with a specialized catheter when the
ronchoscope is seated in the targeted airway. B, Catheter-load
elivery. The valve is constrained within a flexible delivery
atheter that is deployed through the working channel of the
exible bronchoscope.and Cardiovascular Surgery ● Volume 133, Number 1 73.e2
